Last reviewed · How we verify
M108 monoclonal antibody — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
M108 monoclonal antibody (M108 monoclonal antibody) — FutureGen Biopharmaceutical (Beijing) Co., Ltd. M108 is a monoclonal antibody that targets a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or block pathogenic signaling.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| M108 monoclonal antibody TARGET | M108 monoclonal antibody | FutureGen Biopharmaceutical (Beijing) Co., Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- M108 monoclonal antibody CI watch — RSS
- M108 monoclonal antibody CI watch — Atom
- M108 monoclonal antibody CI watch — JSON
- M108 monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). M108 monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/m108-monoclonal-antibody. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab